8 July 2021 - Tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population across Phase 2 and 3 clinical trials.
AstraZeneca’s biologics license application for tezepelumab has been accepted and granted priority review for the treatment of asthma from the US FDA.